TrialThe Lancet. Oncology2019

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Tanios S Bekaii-Saab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.